IQVIA IQV
IQVIA is a global company that combines data analytics, advanced technology, and clinical research services to help pharmaceutical and life sciences companies develop and market drugs more efficiently. IQVIA shows a high-quality business with a 22.82% ROE and 70.53% cash conversion, but its financial health is strained by net debt of 4.65x EBITDA, which raises financing costs amid rising rates; 8.70% revenue growth and a forward P/E of 18.70 offer a reasonable balance.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
IQVIA is a global company that combines data analytics, advanced technology, and clinical research services to help pharmaceutical and life sciences companies develop and market drugs more efficiently. IQVIA shows a high-quality business with a 22.82% ROE and 70.53% cash conversion, but its financial health is strained by net debt of 4.65x EBITDA, which raises financing costs amid rising rates; 8.70% revenue growth and a forward P/E of 18.70 offer a reasonable balance.
Score by category
| Category | Score |
|---|---|
| Financial health | 3.1 |
| Quality / Moat | 6.5 |
| Valuation | 4.6 |
| Growth | 5.4 |
| Dividend | 1.5 |
| Momentum | 8.5 |
| Risk & Context | 4.9 |
OVERALL SCORE: 5.0/10
Context and risks
IQVIA operates in the defensive healthcare sector with no direct exposure to commodities or rates. However, its high leverage (net debt/EBITDA of 4.65) and the $2B notes issuance make it sensitive to the rise in Treasury yields to 5.17%, increasing its debt costs.
News considered in the analysis
- IQVIA Holdings (IQV) Prices $2b Notes, Does The Stock Look Fairly Valued? — Emisión de deuda de 2.000 millones que, con una Deuda Neta/EBITDA ya en 4.65, agrava el apalancamiento y el coste financiero en un entorno de tipos al alza.
- IQVIA (IQV) Stock Could Be Undervalued After Its 42% Run — Análisis de valoración sin información nueva; el mercado ya ha descontado la subida.
- IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know — Resumen de la revalorización pasada, sin catalizadores futuros; el momentum ya está en el precio.
- A Strong Rebound Case of IQVIA Holdings (IQV) — Tesis de rebote basada en la recuperación de la demanda de ensayos clínicos; posible pero no confirmada.
- Can Doximity Keep Shrinking Its Share Count Through Its AI Investment Year? — Noticia sobre un competidor sin impacto directo en los fundamentales de IQVIA.
Verdict: Hold; business quality and reasonable forward valuation offset leverage risk, but there is no clear catalyst to add positions.
Main risk: High leverage (net debt/EBITDA of 4.65) combined with rising Treasury rates, which increases refinancing costs for the $2B notes issued and pressures the 13.03% operating margin.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →